Market Access/ News/ News FDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stable Phil Taylor Duchenne muscular dystrophy, Exondys 51, golodirsen, Sarepta, Vyondys 53 0 Comment The FDA has rejected Sarepta Therapeutics’ new Duchenne muscular dystrophy (DMD) Vyondys 53 due to concerns about potential Share X FDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stable https://pharmaphorum.com/news/fda-says-no-to-sarepta-blocking-bid-to-expand-its-duchenne-stable/